Skip to main content

Table 1 Baseline demographics and disease severity by ADT group (safety sample)

From: Comparison of adjunctive use of aripiprazole with bupropion or selective serotonin reuptake inhibitors/serotonin–norepinephrine reuptake inhibitors: analysis of patients beginning adjunctive treatment in a 52-week, open-label study

Baseline characteristic Bupropion plus aripiprazole (n = 46) SSRI/SNRI plus aripiprazole (n = 242)
Age (years), mean (SD) 45.0 (12.9) 46.6 (12.6)
Gender, n (%)   
  Females 30 (65.2) 166 (68.6)
Race, n (%)   
  White 40 (87.0) 223 (92.1)
  Black 4 (8.7) 12 (5.0)
  Asian 0 2 (0.8)
  Other 2 (4.3) 5 (2.1)
Weight (kg), mean (SD) 93.4 (23.2) 87.7 (22.4)
BMI (kg/m2), mean (SD) 32.5 (8.6) 31.2 (8.1)
CGI-S score, mean (SD) 4.2 (0.6) 4.2 (0.6)
MADRS Total score, mean (SD) 24.5 (4.8) 25.1 (6.0)
IDS-Self Rated Total score, mean (SD) 34.6 (9.4) 38.2 (10.5)
QIDS-Self Rated Total score, mean (SD) 13.5 (3.9) 14.6 (4.2)
  1. CGI-S, Clinical Global Impressions–Severity score; IDS, Inventory of Depressive Symptomatology; MADRS, Montgomery–Åsberg Depression Rating Scale; QIDS, Quick Inventory of Depressive Symptomatology; SD, standard deviation; SNRI, serotonin–norepinephrine reuptake inhibitor; SSRI, selective serotonin reuptake inhibitor.